124 related articles for article (PubMed ID: 8739025)
1. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.
Waldman SA; Vitow C; Osborne B; Gillen L; Argentieri DC; Wong FA; Smith IL; Chow AT; Misiti J; Bjornsson TD
J Clin Pharmacol; 1996 May; 36(5):462-8. PubMed ID: 8739025
[TBL] [Abstract][Full Text] [Related]
2. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.
Depré M; Van Hecken A; Verbesselt R; Verpooten GA; Arnout J; Brunner F; Jurgens A; Pousset V; Chow A; Baldauf C; Vermylen J; De Broe M; De Schepper PJ
Int J Clin Pharmacol Res; 1996; 16(1):1-8. PubMed ID: 9001924
[TBL] [Abstract][Full Text] [Related]
3. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of tepoxalin in the horse: a PK/PD study.
Giorgi M; Cuniberti B; Ye G; Barbero R; Sgorbini M; Vercelli C; Corazza M; Re G
Vet J; 2011 Oct; 190(1):143-9. PubMed ID: 21036634
[TBL] [Abstract][Full Text] [Related]
5. Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase.
Kazmi SM; Plante RK; Visconti V; Taylor GR; Zhou L; Lau CY
J Cell Biochem; 1995 Feb; 57(2):299-310. PubMed ID: 7759567
[TBL] [Abstract][Full Text] [Related]
6. [Novel synthetic method and analgesic activity of tepoxalin].
Guo XH; Zhang HW; Tao L; Li YJ; Wang PA; Wang SY; Wang Q; Dong LH; Chang JB
Yao Xue Xue Bao; 2010 Oct; 45(10):1260-4. PubMed ID: 21348304
[TBL] [Abstract][Full Text] [Related]
7. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs.
Knight EV; Kimball JP; Keenan CM; Smith IL; Wong FA; Barrett DS; Dempster AM; Lieuallen WG; Panigrahi D; Powers WJ; Szot RJ
Fundam Appl Toxicol; 1996 Sep; 33(1):38-48. PubMed ID: 8812216
[TBL] [Abstract][Full Text] [Related]
8. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.
Kirchner T; Aparicio B; Argentieri DC; Lau CY; Ritchie DM
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):417-23. PubMed ID: 9223651
[TBL] [Abstract][Full Text] [Related]
9. Single and multiple-dose pharmacokinetics of tepoxalin and its active metabolite after oral administration to rabbits (Oryctolagus cuniculus).
Pollock CG; Carpenter JW; Koch DE; Hunter RP
J Vet Pharmacol Ther; 2008 Apr; 31(2):171-4. PubMed ID: 18307510
[TBL] [Abstract][Full Text] [Related]
10. Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
Goodman LA; Torres BT; Reynolds LR; Budsberg SC
Am J Vet Res; 2010 Sep; 71(9):1067-73. PubMed ID: 20807147
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
[TBL] [Abstract][Full Text] [Related]
12. Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities.
Tam SS; Lee DH; Wang EY; Munroe DG; Lau CY
J Biol Chem; 1995 Jun; 270(23):13948-55. PubMed ID: 7775455
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic effects of tepoxalin, a cyclooxygenase/lipoxygenase dual inhibitor, on canine synovial fibroblasts.
Sunaga T; Oh N; Hosoya K; Takagi S; Okumura M
J Vet Med Sci; 2012 Jun; 74(6):745-50. PubMed ID: 22240988
[TBL] [Abstract][Full Text] [Related]
14. Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression.
Zhou L; Pope BL; Chourmouzis E; Fung-Leung WP; Lau CY
Eur J Immunol; 1996 Jan; 26(1):120-9. PubMed ID: 8566054
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of tepoxalin, sodium-salicylate and ketoprofen in an intravenous lipopolysaccharide inflammation model in broiler chickens.
de Boever S; Neirinckx EA; Meyer E; de Baere S; Beyaert R; de Backer P; Croubels S
J Vet Pharmacol Ther; 2010 Dec; 33(6):564-72. PubMed ID: 21062309
[TBL] [Abstract][Full Text] [Related]
16. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion.
Kushida I; Ichikawa M; Asakawa N
J Pharm Sci; 2002 Jan; 91(1):258-66. PubMed ID: 11782915
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis.
Agnello KA; Reynolds LR; Budsberg SC
Am J Vet Res; 2005 Jun; 66(6):966-72. PubMed ID: 16008217
[TBL] [Abstract][Full Text] [Related]
19. The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines.
Loftus JP; Cavatorta D; Bushey JJ; Levine CB; Sevier CS; Wakshlag JJ
Vet Comp Oncol; 2016 Jun; 14(2):e17-30. PubMed ID: 24813477
[TBL] [Abstract][Full Text] [Related]
20. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
